Table 15.
Clinical studies in prostate cancer.
| Patient group | Treatment | Participants (n) | Trial, ID | Outcomes | Reference |
|---|---|---|---|---|---|
| AR-V7-expressing metastatic prostate cancer | Nivolumab + ipilimumab | 15 | Phase 2, NCT02601014 |
ORR: 25% Median PFS: 3.7 months Median OS: 8.2 months Grade 3–4 AEs: 46% |
Boudadi et al., 2018 (156) |
| Metastatic castration-resistant prostate cancer (mCRPC) | Nivolumab + ipilimumab | 90 (pre-chemo=45, post-chemo=45) |
Phase 2, NCT02985957 (CheckMate 650) |
ORR: 25% | 10% Median OS: 19.0 months | 15.2 months Grade 3–4 AEs: 42.2% | 53.3% |
Sharma et al., 2020 (157) |
AE, adverse event; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.